Global Blood Therapeutics, Inc. ( GBT) Stock. Should you Buy or Sell? $ 67.76
-0.22 (-0.33 %)
Global Blood Therapeutics, Inc. Analysis
Updated on 10-09-2022| Symbol | GBT |
| Price | $67.76 |
| Beta | 0.833 |
| Volume Avg. | $3.33 M |
| Market Cap | $4.57 B |
| 52 Week Range | $21.65 - $73.02 |
Global Blood Therapeutics, Inc. opened the day at $67.76 which is -0.33 % on yesterday's close. Global Blood Therapeutics, Inc. has a 52 week high of $73.02 and 52 week low of $21.65, which is a difference of $51.37. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $4.57 B and total net profit is $194749000 which means the company is trading at 23.47 times profit to market capitalization. Theoretically, if you were to buy Global Blood Therapeutics, Inc. for $4.57 B, it would take 15 years to get your money back. Global Blood Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Global Blood Therapeutics, Inc. Stock Forecast - Is Global Blood Therapeutics, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Strong Sell | |
| ROA Score | Neutral | |
| DE Score | Strong Buy | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Buy |
Growth and Value
| PE Ratio | -13.784 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -1.373 |
Valuing Global Blood Therapeutics, Inc.
| Price Book Value Ratio | 37.552 | Price To Book Ratio | 37.552 |
| Price To Sales Ratio | 18.925 | Price Earnings Ratio | -13.784 |
How liquid is Global Blood Therapeutics, Inc.
| Current Ratio | 6.875 |
| Quick Ratio | 5.875 |
Debt
| Debt Ratio | 0.864 | Debt Equity Ratio | 6.354 |
| Long Term Debt To Capitalization | 0.846 | Total Debt To Capitalization | 0.848 |
Latest news about Global Blood Therapeutics, Inc.
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the delivery, development and discovery of life-changing medical treatment, Global Blood Therapeutics, for $5.4 billion, representing $68.50 per GBT share.
Pfizer Inc (NYSE:PFE) is to pay US$5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc (NASDAQ:GBT) (GBT) as the pharma major looks to leverage the booming revenue from its Covid-19 vaccine and treatment. Pfizer will pay US$68.50 per GBT share, which represents a 7.3% premium over Friday's closing price and nearly 43% over Thursday's closing price.
The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.
About Global Blood Therapeutics, Inc.
Description :
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
